Jump to Main Content
Biomarkers in patients with myocardial fibrosis
- An, Zhe, Yang, Guang, Zheng, Haikuo, Nie, Wei, Liu, Guohui
- Open life sciences 2017 v.12 no.1 pp. 337-344
- biomarkers, biopsy, cardiomyopathy, collagen, fibrosis, galectins, heart failure, hypertension, microRNA, patients, transforming growth factor beta
- Myocardial fibrosis is observed in many cardiovascular diseases including hypertension, heart failure and cardiomyopathy. Myocardial fibrosis has been proved to be reversible and treatable only under timely intervention, which makes early detection and assessment of fibrosis crucial. Aside from tissue biopsy as the gold standard for the diagnosis of myocardial fibrosis, circulating biomarkers have been adopted as noninvasive assessment of this lesion. Dysregulated collagen deposition is thought to be the major cause of myocardial fibrosis. Collagens, procollagens, TGF-β, TIMP, galectin-3, and microRNAs are thought to be indicators of myocardial fibrosis. In this review, we summarize the molecules that are frequently used as biomarkers in diagnosis of cardiac fibrosis. Mechanisms of fibrosis that they take part in are also introduced.